New cancer clinical trial: XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

Published on: April 27, 2018 at 12:00PM
Conditions:   Colorectal Neoplasms;   Chemotherapy
Interventions:   Drug: XELIRI + bevacizumab;   Drug: XELOX + bevacizumab
Sponsors:   Harbin Medical University;   Cancer Institute and Hospital, Chinese Academy of Medical Sciences;   Fudan University;   Sun Yat-sen University;   First Affiliated Hospital of Harbin Medical University;   The Second Affiliated Hospital of Harbin Medical University;   Liaoning Tumor Hospital & Institute;   Shengjing Hospital;   First Hospital of Jilin University;   The First Affiliated Hospital of Dalian Medical University;   Jilin Provincial Tumor Hospital;   The first affiliated hospital of Jinzhou Medical University
Recruiting
https://ift.tt/2HDWbLp